预处理血小板增多症可预测子宫内膜癌患者预后不良：系统评价和荟萃分析。
Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis.
机构信息
Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, No. 20 Section 3, Renmin South Road, Chengdu, Sichuan, 610041, People's Republic of China.
Department of Obstetrics and Gynecology, The affiliated hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China.
出版信息
BMC Cancer. 2019 Jan 15;19(1):73. doi: 10.1186/s12885-018-5264-y.
BACKGROUND
Several previous studies have confirmed that thrombocytosis was related to reduced survival in many solid tumors. However, the prognostic significance of thrombocytosis in endometrial carcinoma (EC) was still controversy. Therefore, we conducted this study to assess the prognostic value of thrombocytosis in EC.
METHODS
The database including PubMed, MEDLINE, EMBASE, and Web of Science was searched to explore available literature. Above all, the hazard ratio (HR), odds ratios (OR) with 95% confidence intervals (CIs) was used to investigate the correlation between thrombocytosis and overall survival (OS) and disease-free survival (DFS). Moreover, the association between thrombocytosis and patient clinicopathological characteristics was explored. Publication bias and sensitivity analysis also were conducted in this study.
RESULTS
Overall, 11 studies involving 3439 patients were contained in this study. The results revealed that pretreatment thrombocytosis was significantly related to a decreased OS (pooled HR = 2.99; 95% CI = 2.35-3.8; P < 0.001) and DFS (pooled HR = 2.86; 95% CI = 2.27-3.6; P < 0.001) in patients with EC. Moreover, thrombocytosis was correlated with adverse clinicopathological parameters.
CONCLUSIONS
Pretreatment thrombocytosis is an adverse prognostic marker in patients with EC.
背景
多项先前的研究已经证实，血小板增多与许多实体瘤的生存率降低有关。然而，血小板增多在子宫内膜癌（EC）中的预后意义仍存在争议。因此，我们进行了这项研究，以评估血小板增多在 EC 中的预后价值。
方法
我们检索了包括 PubMed、MEDLINE、EMBASE 和 Web of Science 在内的数据库，以探索可用的文献。总之，使用风险比（HR）、优势比（OR）和 95%置信区间（CI）来研究血小板增多与总生存（OS）和无病生存（DFS）之间的相关性。此外，还探讨了血小板增多与患者临床病理特征之间的关系。本研究还进行了发表偏倚和敏感性分析。
结果
共有 11 项研究纳入了 3439 名患者。结果表明，治疗前血小板增多与 OS（合并 HR=2.99；95%CI=2.35-3.8；P<0.001）和 DFS（合并 HR=2.86；95%CI=2.27-3.6；P<0.001）降低显著相关。此外，血小板增多与不良临床病理参数相关。
结论
治疗前血小板增多是 EC 患者的不良预后标志物。
Zotero 插件